GenSight Biologics (ENXTPA:SIGHT) - Share price, News & Analysis

SIGHT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

SIGHT Stock Overview

Rewards

Trading at 63.7% below our estimate of its fair value

Revenue is forecast to grow 47.85% per year

Risk Analysis

Earnings are forecast to decline by an average of 8.2% per year for the next 3 years

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

GenSight Biologics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GenSight Biologics
Historical stock prices
Current Share Price	€2.12
52 Week High	€10.08
52 Week Low	€1.80
Beta	2.82
1 Month Change	1.44%
3 Month Change	-37.52%
1 Year Change	-76.58%
3 Year Change	48.11%
5 Year Change	-69.08%
Change since IPO	-74.01%

Shareholder Returns

	SIGHT	FR Biotechs	FR Market
7D	6.3%	0.4%	-2.9%
1Y	-76.6%	-42.0%	-6.3%

Return vs Industry: SIGHT underperformed the French Biotechs industry which returned -39.9% over the past year.

Return vs Market: SIGHT underperformed the French Market which returned -18.8% over the past year.

Price Volatility

Is SIGHT's price volatile compared to industry and market?
SIGHT volatility
SIGHT Average Weekly Movement	13.0%
Biotechs Industry Average Movement	8.7%
Market Average Movement	6.0%
10% most volatile stocks in FR Market	10.1%
10% least volatile stocks in FR Market	3.5%

Stable Share Price: SIGHT is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: SIGHT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

Founded	Employees	CEO	Website
2012	33	Bernard Gilly	https://www.gensight-biologics.com

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase III clinical trial for the treatment of retinitis pigmentosa, as well as in Phase I/II clinical trial to treat dry age-related macular degeneration.

GenSight Biologics Fundamentals Summary

How do GenSight Biologics's earnings and revenue compare to its market cap?
SIGHT fundamental statistics
Market Cap	€97.28m
Earnings (TTM)	-€28.60m
Revenue (TTM)	€7.70m

12.6x

P/S Ratio

-3.4x

P/E Ratio

Is SIGHT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
SIGHT income statement (TTM)
Revenue	€7.70m
Cost of Revenue	€0
Gross Profit	€7.70m
Other Expenses	€36.30m
Earnings	-€28.60m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Jul 28, 2022

Earnings per share (EPS)	-0.62
Gross Margin	100.00%
Net Profit Margin	-371.43%
Debt/Equity Ratio	57.3%

How did SIGHT perform over the long term?

See historical performance and comparison

Valuation

Is GenSight Biologics undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: SIGHT (€2.12) is trading below our estimate of fair value (€5.83)

Significantly Below Fair Value: SIGHT is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: SIGHT is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Biotechs industry average.

PE vs Market: SIGHT is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SIGHT's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: SIGHT is overvalued based on its Price-To-Book Ratio (3x) compared to the FR Biotechs industry average (2.6x).

Future Growth

How is GenSight Biologics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-8.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SIGHT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SIGHT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SIGHT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SIGHT's revenue (47.9% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: SIGHT's revenue (47.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SIGHT's Return on Equity is forecast to be high in 3 years time

Past Performance

How has GenSight Biologics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-5.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SIGHT is currently unprofitable.

Growing Profit Margin: SIGHT is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: SIGHT is unprofitable, and losses have increased over the past 5 years at a rate of 5.3% per year.

Accelerating Growth: Unable to compare SIGHT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SIGHT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: SIGHT has a negative Return on Equity (-86.94%), as it is currently unprofitable.

Financial Health

How is GenSight Biologics's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SIGHT's short term assets (€64.1M) exceed its short term liabilities (€17.4M).

Long Term Liabilities: SIGHT's short term assets (€64.1M) exceed its long term liabilities (€17.1M).

Debt to Equity History and Analysis

Debt Level: SIGHT has more cash than its total debt.

Reducing Debt: SIGHT's debt to equity ratio has increased from 5.5% to 57.3% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SIGHT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: SIGHT has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 1.2% each year.

Dividend

What is GenSight Biologics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

11.33%

Forecast Dividend Yield

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SIGHT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SIGHT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SIGHT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SIGHT's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SIGHT has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure

CEO

Bernard Gilly (64 yo)

11.33yrs

Tenure

€2,438,633

Compensation

Dr. Bernard Gilly, Ph.D. serves as Chairman at iBionext. He is Independent Chairman at EyeTechCare SA. He serves as President and Chairman of the Board at ChronoLife SAS.He co-founded Fovea Pharmaceutical...

CEO Compensation Analysis

Compensation vs Market: Bernard's total compensation ($USD2.62M) is above average for companies of similar size in the French market ($USD290.45K).

Compensation vs Earnings: Bernard's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: SIGHT's management team is considered experienced (4.5 years average tenure).

Board Members

Experienced Board: SIGHT's board of directors are seasoned and experienced ( 10.1 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/24 00:00
End of Day Share Price	2022/05/24 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31